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ABSTRACT
Background
New treatment options offering enhanced activity in elderly, newly diagnosed patients with multiple
myeloma are required. One strategy is to combine melphalan and prednisone with novel agents.
We previously reported an 89% response rate, including 32% complete responses and 11% near
complete responses, in our phase 1/2 study of bortezomib plus melphalan and prednisone (VMP)
in 60 newly diagnosed multiple myeloma patients with a median age of 75 years. Here, we report
updated time-to-events data and the impact of poor prognosis factors on outcome.
Design and Methods
Updated analyses of time to biochemical progression and overall survival with VMP were con-
ducted, and compared with those of historical controls treated with melphalan and prednisone.
A univariate analysis was performed to evaluate the influence of known prognostic factors on the
time to progression.
Results
After a median follow-up of 26 months, the median time to progression with VMP was 27.2 months,
compared with 20.0 months with melphalan plus prednisone. The median overall survival with VMP
was not reached versus 26 months with melphalan and prednisone; the survival rate at 38 months
was 85% versus 38%, respectively. Time to progression was not significantly affected by elevatedβ2-microglobulin or lactate dehydrogenase levels, advanced age, or cytogenetic abnormalities, but
was shorter in patients with albumin <3 g/dL, Karnofsky performance status ≤70%, bone marrow
plasma cell infiltration ≥40%, and, particularly, high plasma cell proliferative activity (≥2.5% S-
phase cells).
Conclusions
VMP is highly active and well tolerated in elderly patients with newly diagnosed muktiple myelo-
ma, with 85% of patients alive at 3 years. Moreover, VMP may overcome the poor prognostic
impact of various factors, particularly cytogenetic abnormalities.
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Introduction
Melphalan plus prednisone (MP) is a standard of care
for elderly newly diagnosed patients with multiple
myeloma. However, its efficacy remains disappointing,
with median progression-free survival and overall sur-
vival typically ranging between 17–21 months and 2–3
years, respectively.1-3 New treatment options offering
enhanced activity are required for this population of
patients.
In order to improve outcomes in elderly patients with
multiple myeloma, the combination of MP with novel
agents that have marked activity in relapsed/refractory
multiple myeloma has been investigated recently.4-8
Thus, MP plus thalidomide has already demonstrated
superiority versus MP.5-7 We have previously reported
that the proteasome inhibitor bortezomib may be com-
bined successfully with MP (VMP regimen) in the treat-
ment of elderly patients with newly diagnosed multiple
myeloma, with a predictable and manageable safety
profile.4 The combination demonstrated substantial
activity, with a response rate of 89%, including 32%
complete responses and 11% near complete responses,4
the highest complete/near complete response rate
reported with MP-based regimens to date.5-10 In addi-
tion, responses to VMP were not influenced by cytoge-
netic abnormalities. The response rate was higher than
that among MP-treated historical controls, and 16-
month progression-free survival, event-free survival,
and overall survival rates were significantly greater
with VMP than with MP.
Here, we report updated time to biochemical pro-
gression and overall survival data from our study of eld-
erly subjects with multiple myeloma treated with VMP.
Design and Methods
Study design
The design of this phase 1/2, dose-escalation study,
conducted at 19 centers in Spain for the PETHEMA
Foundation, has already been reported.4 Briefly, eligible
patients were aged ≥65 years and had newly diag-
nosed, previously untreated, symptomatic multiple
myeloma with measurable disease.11 Patients received
bortezomib 1.0 mg/m2 (n=6) or 1.3 mg/m2 (n=54) on
days 1, 4, 8, 11, 22, 25, 29, and 32 for four 6-week
cycles, and then on days 1, 8, 15, and 22 for five 5-week
cycles. They also received oral melphalan 9 mg/m2 and
prednisone 60 mg/m2 on days 1–4 of all nine cycles.
The total maximum treatment duration was 49 weeks.
Patients discontinued treatment if they had progressive
disease, developed unacceptable toxicity, withdraw
consent, or maintained a confirmed complete response
for two cycles.4 Disease response was assessed using
European Group for Blood and Marrow Transplant-
ation (EBMT) criteria11 at the start of each cycle, at an
end-of-treatment visit, and every 8 weeks for at least 6
months during the follow-up. Thereafter, patients were
followed up every 3 months for survival.
This study was conducted in accordance with
International Conference on Harmonisation Good
Clinical Practice guidelines and the Declaration of
Helsinki and was approved by the Institutional Review
Board/Independent Ethics Committee at each partici-
pating center. All patients provided written informed
consent before screening. Data were monitored by an
independent/external contract research organization.
Assessments
Updated analyses of time to progression, event-free
survival and overall survival in patients treated with
VMP were conducted, and compared with historical
control data from a similar population of patients treat-
ed with MP.12 Time to alternative treatment (the time
from inclusion in the study to initiation of an alterna-
tive myeloma therapy) was analyzed. To evaluate the
influence of known myeloma prognostic factors on
time to progression, a univariate analysis was conduct-
ed (log-rank for categorical variables, coded into cate-
gories with presumed better-to-worse prognosis).
Variables included were: sex, age, M-protein class,
International Staging System13 stage, Karnofsky per-
formance status, β2-microglobulin level, lactate dehy-
drogenase level, serum albumin, plasma-cell bone mar-
row infiltration, percentage of plasma cells in S-phase,
and cytogenetic abnormalities detected by fluorescence
in situ hybridization analysis.
Results
The patients’ demographics and baseline characteris-
tics have been reported previously; their median age
was 75 years.4
Updated time-to-events data
All 60 patients received at least one dose of borte-
zomib, and were evaluable for time to progression and
overall survival analyses. After a median follow-up of
26 months (range, 15–38 months), the median time to
progression with VMP was 27.2 months, compared
with 20.0 months among historical controls treated
with MP (Figure 1A; p=0.001). The median event-free
survival was 25.0 months, compared with 15.0 months
among the historical controls p=0.001), and the event-
free survival distribution curve (Figure 1B) was similar
to that for time to progression. The median overall sur-
vival has not been reached with VMP, compared with
26 months with MP (Figure 1C; p<0.0001); the overall
survival rate at 38 months is 85% with VMP versus
38% with MP (p<0.0001). 
Among 25/60 (42%) patients receiving VMP who
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have relapsed to date, 10/25 (40%) experienced bio-
chemical but asymptomatic relapse. Of these ten
patients, seven remain untreated, with a median fol-
low-up from biochemical relapse of 5 months (range,
1–8 months). Consequently, the median time to alter-
native treatment has not been reached. 
Influence of prognostic factors on time to progression
Table 1 shows the influence of the most important
prognostic factors on median time to progression
according to invariate analysis (the small sample size
precluded the use of multivariate analysis). The median
time to progression was significantly shorter in patients
with albumin <3 g/dL, Karnofsky perfomance status
≤70%, bone marrow plasma-cell infiltration ≥40%, or,
particularly, ≥2.5% plasma cells in the S-phase, com-
pared with corresponding subgroups. It should be
noted that these patients with a high proportion of S-
phase plasma cells initially responded to VMP, but
showed early disease progression with a markedly
shorter time to progression (15 months). This finding
has not been reported previously, and may contribute
to our understanding of the mechanisms involved in
secondary resistance to bortezomib.
By contrast, β2-microglobulin and lactate dehydroge-
nase levels, International Staging System stage, age,
and cytogenetic abnormalities (Rb deletion/chromo-
some 13 deletion and IgH translocations such as t(4;14)
and t(14;16)) did not significantly affect the median
time to progression (Figure 1D and 1E). In six patients,
chromosome 13 deletion and IgH translocations coex-
isted. This cytogenetic profile has been associated with
a poor prognosis,14 but the median time to progression
with VMP in these six patients did not differ signifi-
cantly from that of patients with normal cytogenetics
(Figure 1E).
Safety
The VMP safety profile was unchanged from our pre-
vious report.4 VMP was well tolerated in this elderly
population of patients; toxicities were predictable and
manageable.4 The most common toxicities are listed in
Table 2.
Discussion
These updated time-to-events results, following pro-
longed follow-up, from our phase 1/2 study of VMP in
patients with newly diagnosed multiple myeloma rep-
resent extremely promising outcomes and confirm the
substantial activity of VMP in terms of prolonged time
to progression and overll survival in this elderly patient
population. Indeed, the survival rate with VMP at 3
years is the highest reported to date with MP-based
regimens.5-10 These data indicate that, while until
recently more than half of patients receiving MP thera-
py would have died by this time point, with VMP the
majority (85%) of patients will be alive at 3 years. This
is particularly notable considering the advanced age of
the patients in this study (half were aged ≥75 years).
However, it is important to note that the potential
benefit on overall survival observed with VMP may
also be partly due to differences in subsequent treat-
ments that patients received at the time of the MP
study and those currently used. In fact, fewer than 25%
of the historical controls treated with MP received res-
cue therapy with novel agents.
The prolonged time to alternative therapy among
patients who experienced biochemical but asympto-
matic relapse represents the clinical benefit of VMP in
elderly patients more effectively than the time to pro-
gression. Patients who remain off-treatment beyond
biochemical relapse are spared from not only the return
of their symptoms but also toxicities associated with
commencing an alternative anti-myeloma treatment.
The difference between the time to alternative treat-
ment and the time to progression is of particular rele-
vance in our study of VMP given the high number of
patients achieving a complete response (immunofixa-
tion-negative for M-protein; 32%). In these patients,
the time to progression may be adversely affected since
a change to immunofixation-positive status (a bio-
Table 1. Influence of prognostic factors on median time to pro-
gression among patients treated with VMP.
Factor n Median TTP, months p value
Albumin
≥3 g/dL 43 29 0.02
<3 g/dL 11 15
Karnofsky performance status
>70% 36 Not reached 0.004
≤70% 19 19
Bone marrow plasma-cell infiltration
<40% 33 Not reached 0.02
≥40% 24 24
Plasma cells in S-phase
<2.5% 27 Not reached <0.0001
≥2.5% 10 15
LDH level
Normal 44 27 0.1
High 7 22
β2-microglobulin level
<3.5 mg/L 25 23 0.4
≥3.5 mg/L 29 29
ISS Stage
I/II 44 27 0.2
III 10 24
Age
75 years 36 27 0.3
>75 years 24 29
Cytogenetic abnormalities
No Rb del 20 Not reached 0.3
Rb del 13 25
IgH –ve/no Rb del 23 29 0.3
IgH +ve/Rb del 6 23
IgH, immunoglobulin heavy chain; ISS, International Staging System; TTP, time
to progression; LDH, lactate dehydrogenase; Rb, retinoblastoma.
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chemical relapse) would count as an event in Kaplan-
Meier analysis of time to progression, despite the
absence of any other signs of disease activity. The pos-
sibility that the strict definition of relapse from com-
plete response by EBMT criteria could lead to a para-
doxically shorter remission duration in patients achiev-
ing a complete response than in those achieving a par-
tial response was suggested by Bladé et al. when the cri-
teria were first introduced.11
The findings from our univariate analysis of the
impact of various prognostic factors on the median
time to progression indicate that VMP may overcome
the poor prognostic impact of factors such as advanced
age,15,16 increased lactate dehydrogenase16 or β2-
microglobulin13 level, advanced International Staging
System stage disease,13 and, particularly, cytogenetic
abnormalities (Rb deletion/chromosome 13 deletion17,18
and IgH translocations).19,20 This is the first prospective
analysis to show that response and, more importantly,
Figure 1. Time to progression (A), event-free survival
(B), and overall survival (C) in patients receiving VMP
and in historical controls treated with MP. The impact of
the presence or absence of retinoblastoma gene dele-
tion (D) and retinoblastoma gene deletion and
immunoglobulin heavy-chain translocation (E) on time
to progression among patients treated with VMP. The
median follow-up among patients receiving VMP is 26
months.
Table 2. Most common (occurring in ≥30% of patients) adverse
events in patients receiving VMP (n=60).
Adverse event Overall toxicities (%)
All grades Grade 3/4
Anemia 86 10
Thrombocytopenia 93 51
Infection 75 16
Neutropenia 85 43
Asthenia 63 5
Nausea 55 2
Diarrhea 55 16
Peripheral neuropathy 55 17
Constipation 52 8
Anorexia 38 2
Vomiting 30 2
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time to progression are not influenced by cytogenetic
abnormalities in patients treated with bortezomib-
based regimens; in support of our findings, two recent
retrospective reports have shown that response rate21,22
and duration of response22 to bortezomib in patients
with relapsed and/or refractory multiple myeloma are
independent of chromosome 13 deletion status deter-
mined by fluorescence in situ hybridization.
By contrast, other poor prognostic factors associated
with high tumor burden and rapidly proliferating dis-
ease, such as low albumin,13 poor Karnosky perform-
ance status, high degree of bone marrow infiltration,23
and a high proportion of S-phase plasma cells,24,25
appear to retain prognostic significance with VMP, as
evidenced by statistically shorter median time to pro-
gression values. The highly significant association
between a high proportion of S-phase plasma cells and
a shorter median time to progression (15 months) is of
particular relevance. This intriguing observation war-
rants further investigation to elucidate why patients
with high tumor proliferative activity, although initial-
ly sensitive to bortezomib, soon become resistant. 
In conclusion, VMP is highly active and well tolerat-
ed, and represents an attractive treatment strategy for
patients aged ≥65 years with newly diagnosed multiple
myeloma. VMP has recently been added as a treatment
option for this population of patients in the US
National Comprehensive Cancer Network Clinical
Practice Guidelines in Oncology for Multiple
Myeloma.26 Results from the large international, ran-
domized phase 3 VISTA (VELCADE as Initial Standard
Therapy in multiple myeloma: Assessment with mel-
phalan and prednisone) trial of VMP compared with
MP in patients aged ≥65 years who are not eligible for
transplantation will further define the differences in
efficacy and outcome between the regimens.
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